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Dan Shu1,2,3, Fengmei Pi1,2,3, Chi Wang,2,4, Peng Zhang5 and Peixuan Guo1,2,3 *
1

Nanobiotechnology Center; 2Markey Cancer Center; 3Department of Pharmaceutical Sciences; 4Department of
Biostatistics; University of Kentucky, Lexington, KY 40536, USA. 5Department of Surgery, University of Michigan
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Abstract
Aims: To find a method for developing potent drugs and to prove a
hypothesis that drug inhibition potency depends on the stoichiometry
of the targeted biocomplex.
Methods: Phi29 DNA-packaging motor components were used to
test this model for different stoichiometries. Virion assembly
efficiency was assayed with Yang Hui's Triangle: ሺ  ݍሻ ൌ





൫ெ
൯ ିெ  ݍெ , where Z=stoichiometry, M=drugged subunits in

ெୀ

each biocomplex, p and q represent the fraction of drugged and
non-drugged subunits in the population.
Results: Inhibition efficiency follows a power function. When number
of drugged subunits to block the function of the biocomplex K=1, the
z
fraction of uninhibited biocomplex equals q . Thus, stoichiometry has
a multiplicative effect on inhibition. Targets with a thousand subunits
showed the highest inhibition effect, followed by those with six and a
single subunit. Complete inhibition of virus replication was found
when Z = 6.
Conclusion: Drug inhibition potency depends on the stoichiometry
of the targeted components of the biocomplex or nano-machine. The
inhibition effect follows a power function of the stoichiometry of the
target biocomplex.
Key words: Drug target, phi29 viral assembly, nanomotor,
hexameric ATPase, bionanotechnology, nanobiotechnology,
binomial distribution.

Introduction
Bacteria, viruses and cells contain biocomplexes and nanomachines
composed of multiple subunits, such as biomotors [1,2,3,4], pumps
[5], exosomes [6,7,8], valves [9,10,11], membrane pores
[12,13,14,15], chaperonins[16], PCNA[17], ATPase [18,19], and
tubes [20]. From a nanobiotechnological standpoint, these
*Address correspondence to: Peixuan Guo, peixuan.guo@uky.edu
Department of Pharmaceutical Sciences, University of Kentucky
789 S. Limestone Street, Room # 576
Lexington, KY, USA 40536-0596
Phone: 859-218-0128
Fax: 859-257-1307

nanomachines can be used and converted to build sophisticated
nano-devices including molecular sensors [21,22,23], patterned
arrays, tuators [24], chips, microelectromechanical systems (MEMS)
[25], molecular sorters [26], single pore DNA sequencing apparatus
[12,13,21,27] or other revolutionary electronic and optical devices
[28,29]. From a pharmaceutical standpoint, these multi-subunit
biocomplexes or nanomachines have a potential for use as drug
targets for therapeutics, as well as diagnostic applications such as
pathogen detection, disease diagnosis, drug delivery, and treatment
of diseases [22,23,30,31]. In the ASCE (Additional Strand Catalytic
E) family including the AAA+ (ATPases Associated with diverse
cellular Activities) and the FtsK-HerA superfamily in bacteria, viruses
and cells, there are nanomotors that perform a wide range of
functions [19,32,33] critical to chromosome segregation, bacterial
binary fission, DNA/RNA and cell component transportation,
membrane sorting, cellular reorganization, cell division, RNA
transcription, as well as DNA replication, riding, repair, and
recombination [1,34,35,36]. One of the directions of NIH Roadmap
is to utilize these cellular nanomachines and biocomplexes for
biomedical applications.
Acquired drug resistance has become a major reason for failure
treatment of a range of diseases, i.e., the chemotherapy for cancer,
bacterial or viral infections. Drug resistance of cancer has escalated
and has partially contributed to the ~600,000 deaths in the USA in
2012 [37]. HIV drug resistance has also become a major issue [38].
Many common pathogens have become resistant to current drug
treatments, with new infectious diseases on the rise. The use of
multidrug-resistant agents in biological weapons has created a
previously unrealized challenge [39]. Thus, there is a need to
develop new treatment strategies to combat drug resistance with
new drug development methods.
The first FDA-approved drug to treat multidrug-resistant tuberculosis,
bedaquiline, follows a novel mechanism of inhibiting the bacterial
ATP synthase of M. tuberculosis and other mycobacterial species,
but had little activity against other bacteria [40]. To combat multidrug
resistance in cancer, several approaches have been explored. One
method is to target components that are highly important for the
growth of the biological entity [41,42]. Another approach uses nanodrug delivery carriers that are expected to enhance the binding
efficiency of drugs to cancer cells[43,44,45,46], or cocktail therapy
[47]. A third approach is to develop new combinational drugs with
higher potency by acting on multiple targets [48,49]. This involves
identifying multiple targets that when treated leads to a synergetic
effect and optimizing the design of multi-target ligands[50].
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Figure 1: Stoichiometry of viral DNA packaging motor. (A) Illustration of Phi29 DNA packaging motor composed of 1 copy of genomic DNA that revolves
through the channel wall (left panel), 6 copies of pRNA, 6 copies of ATPase gp16 and a connector channel. (B) Yang Hui Triangle. (C) Illustration of Z=6 and
K=1, drug targeting anyone subunit of the complex will block its activity. (D) AFM image of hexameric re-engineered pRNA rings. (E). 3D structure of hexameric
pRNA ring top view and side view from the crystal structure of 3WJ (PDB ID: pRNA 3WJ, 4KZ2). (F) A crystal hexameric structure of AAA+ Protein CbbX
withtop view and side view [85] (PDB ID: CbbX, 3Zuh, http://www.ebi.ac.uk/pdbe/emdb/) (G) Structure of the hexameric AAA+ molecular machine ClpC with
adaptor protein MecA. [86] (PDB ID: MecA-ClpC, 3PXG).

The approach of developing highly potent drugs through targeting of
protein or RNA complexes with high stoichiometry has never
been reported due to challenges in comparing efficacies of two drugs
that can be confused by target essentiality with binding affinity. For
instance, if two drugs target two stoichiometrically different targets, it
becomes extremely difficult to prove whether the difference in drug
efficiency is due to differences in their target binding affinity or
essential level in the growth of the biological organism. In order to
quantify effects from targeting biocomplexes of different
stoichiometry, a well-studied multi-component system is required that
allows empirical comparison of functional inhibition of individual
components that are composed of different number of subunits.
An example of one nanobiomachine is the dsDNA translocation
motor, for which the ATPase protein is a pivotal component that
assembles into a hexameric ring structure and translates the action
of ATP binding and hydrolysis into mechanical motion to translocate
DNA physically. The DNA packaging motor of bacteriophage phi29
(Fig. 1A) [9,51,52,53] is composed of three essential co-axial rings:

1) a dodecameric connector ring located at the vertex of the viral
procapsid; 2) a hexameric packaging RNA (pRNA) ring [52] bound
to the N-terminus of the connector [54], and 3) a hexameric ring of
ATPase gp16 attached to the helical region of pRNA [10,19,55],
powered through the hydrolysis of ATP resulting in DNA packaging.
The use of Yang Hui's Triangle (Fig. 1B) or binomial distribution to
determine the stoichiometry of the pRNA was first reported in 1997
[56]. The use of similar mathematical methods to determine the
stoichiometry of the protein subunits has also been reported more
recently [51]. The copy number of ATP molecules required to
package one full phi29 genomic dsDNA was predicted to be 10000
[57]. It has recently been shown that this hexameric motor uses a
revolution mechanism without rotation to translocate its genomic
DNA [10,19,33,35,36,58,59].
In this report, we hypothesize that the inhibitory efficiency of a drug is
related to the stoichiometry of its targeted biocomplex; the higher the
stoichiometry of the target complex, the more efficient the drug. This
can lead to the development of potent therapeutics against highstoichiometric biomachines or biocomplexes as drug targets. We
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proved this hypothesis by using a mutant subunit as the drugged
inactive target to calculate the theoretical inhibition efficiency via
binomial distribution, and compared with experimental data from a
defined in vitro viral assembly system. Since biomotors share certain
common structures and operation mechanisms [1,36,59,60], the
approach in drug development reported here should have general
applications especially in developing new generations of drugs for
combating the rising acquired drug resistance in viruses, bacteria,
and cancers [38,61,62] .

Materials and Methods
Preparation of mutant genomic dsDNA
Phi29 genomic DNA-gp3 was purified from B. subtilis SpoA12 cells
by CsCl gradient ultracentrifugation as described previously [63].
Mutant dsDNA was prepared by digesting the phi29 genomic dsDNA
with EcoR1 restriction enzyme in fast digest buffer (Fermentas) at 37
°C for 1 hour followed by ethanol precipitation. The mutant DNA was
tested by 1% agarose gel electrophoresis, stained by ethidium
bromide (Sigma) and imaged by Typhoon (GE).
Preparation of mutant pRNA
Wild-type phi29 pRNA and inactive mutant as drugged pRNA were
prepared by in vitro transcription. In the inactive mutant pRNA, the
first four bases “UUCA” located at the 5’ end were mutated to
“GGGG”. BglII digested plasmid pRT71 was used as DNA template
[64] in the PCR reaction for both RNAs. Oligonucleotide 5’-TAA TAC
GAC TCA CTA TAG GGG TGG TAC-3’ and 5’-TTA TCA AAG TAG
CGT GCA C-3’ were used as primers for mutant pRNA. RNAs were
then transcribed by T7 RNA polymerase using double-stranded DNA
generated from PCR, as described before [65]. The RNA from in
vitro transcription was further purified by 8 M urea 8%
polyacrylamide gel electrophoresis as described previously [64].
Preparation of mutant ATPase gp16
The purification of wild-type gp16 has been described previously
[63]. The walker B mutant gp16 was constructed by introducing
mutations in the gp16 gene. The amino acid residues D255 and
E256 in walker B motif of gp16 were mutated to E255 and D256,
respectively. The mutation was introduced with the Stratagene Quick
Change site-directed mutagenesis kit using appropriate primers. The
expression and purification of protein were carried out followed a
published procedure [51].
Antisense oligonucleotides
Antisense oligonucleotides P3 and P15 were designed to be
reversely complementary to different regions on the pRNA molecule
and
chemically
synthesized
by
IDT.
P3
oligo
(5’TTGCCATGATTGACAAC-3') targets the region of 83-99 nucleotides
at the 3’end of pRNA, P15 oligo (5’-AAGTACCGTACCATTGA-3')
targets the region of 1-17 nucleotides at the 5’end of pRNA. P8 oligo
(5'-TAATACGACTCACTATAGGGGTGGTAC-3') was designed as a
non-targeting control in the test. 1 μl of individual oligos at 100 μM
were mixed with 1 μl of pRNA at 4 μM and dialyzed on a 0.025 μm
mixed cellulose esters VSWP filter membrane (Millipore Corp)
against TBE buffer (89 mM Tris-HCl, pH 8.3, 89 mM boric acid, 2.5
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mM EDTA) at room temperature for 15 min. The purified RNA
complex was used for in vitro phi29 assembly assay.
In vitro phi29 assembly assay
Purified components were subjected to in vitro viral assembly assay
as described previously [66]. Briefly, 10 μg of purified procapsids
were mixed with 100 ng of pRNA in 5 μl of reaction buffer (10 mM
ATP, 6 mM 2-mercaptoethanol, and 3 mM spermidine in TMS buffer)
at room temperature for 30 min. Purified DNA-gp3 and gp16 were
then added and the reaction mixture was incubated at room
temperature for one hour to initiate DNA packaging. Finally, the DNA
filled procapsids were incubated with 10 μl of gp8.5-9 extract from
E.coli containing plasmid pARgp8.5-9 and 20 μl of gp11-14 extract
from E.coli to complete the infectious phage assembly.
The newly assembled infectious viruses were plated with inoculated
+44
B. subtilis bacteria Su cells onto a half LB plate covered with top
agar. After 12 hour incubation at 37 °C, the viral assembly efficiency
(plaque-forming unit, PFU) was calculated by counting the formed
plaque numbers. Mixing different ratios of mutant with wild-type
components, while keeping all other components the same, the viral
assembly efficiency (PFU) versus ratio of mutant components gave
an empirical curve for vial assembly inhibition assay, and it was
compared with theoretical curves from the binomial distribution
equation.
In vivo viral assembly assay
Plasmid pRBwtRNA containing the pRNA coding sequence under T7
promoter was constructed by ligating the fragment coding pRNA
sequence and T7 promoter into pRB381-L550 vector (modified and
kindly provided by M. Wang and H. Zalkin) following a previously
described method [67]. Plasmid pRBmutRNA contained mutant
pRNA under its natural promoter PE1 sequence, and the mutation
was changing sequence 5’UUGA-3’ at its 3’end to 5’GGGG-3’. The
DNA fragments coding mutant pRNA sequence and PE1 sequence
were prepared by PCR as described previously[67]; and digested
with HindIII-BglII restriction enzyme. The mutant pRNA sequence
coding fragment was further ligated with a 6.0kb fragment from
pRB381-L550 that was digested with HindIII and partially digested
with BglII.
The plasmids pRBmutRNA, pRBwtRNA, and pRB381-L550 were
transformed into B. subtilis cells following methods described
previously [67]. The B. subtilis cells harboring transformed plasmids
were incubated in 416 medium with 10 mg/ml of neomycin for 3
hours at 37 °C and then plated onto LB-neomycin (10 mg/ml) plates
for plaque formation analysis.

Results
The Definition of "Stoichiometry"
The definition of the stoichiometry in this report is different from
conventional definition of stoichiometry used to evaluate drug
efficiency. Conventionally the concept of stoichiometry refers to the
number of a drug binding to each target molecule, which is also
known as Bmax. In this study the definition of stoichiometry refers to
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the copy number of subunit within a biocomplex or the nanomachine
that serves as drug target.
The definition of "K value", and K = 1 is one key for ultra-high
inhibition efficacy
Suppose a biocomplex drug target contains Z copies of subunits,
then K is the copy number (K ≤ ܼ) of drugged subunits required to
inhibit the function of the complex or the nanomachine. As an
analogy to the difference between the parallel circuit and the serial
circuit, when the Christmas lights are arranged in a parallel circuit,
any light bulbs that are burnt out will not affect other bulbs. But in a
serial circuit, any one light bulb that is broken will stop the entire
lighting system, which is K=1. Thus, the K value is the key to the
probability of inactive nanomachines or biocomplexes by
combination and permutation of all subunits. K equals 1 is critical for
such ultra-high inhibition effect. The foundation of the approach in
this report is the difference in probability of inhibited biocomplexes in
systems of different K values with combination and permutation
algorithms. Biological systems display complicated reactions. Many
reactions involve multiple subunits to work cooperatively sequentially
or processively to accomplish one essential biological function
[33,68,69,70,71,72,73,74,75]. Single assembly pathways have been
reported in the viral assembly system [76,77]. In most cases of the
sequential, cooperative, and precessive action, inactivation of any
one, not necessary all, of the subunits will result in inhibition of its
function, thus K =1. Drug synergism was utilized in multi-target drug
therapy; in short, a drug combination can simultaneously act on
multiple targets in disease networks to produce a synergistic effect
[50,78]. However, our design reported here is unique from the
conventional synergistic approach. We suggest that using multisubunit biocomplexes as drug target could lead to development of
ultra-high potent drugs. In a conventional six-component system, for
example one drug is designed to target component #3 to stop the
entire system, since the drug can only target component #3, the
condition fits the model of Z=1 and K=1. Thus, the inhibition
efficiency and substrate targeting efficiency (p) of drug will be in
linear relationship. However, in the system in this report, the entire
system will be blocked when drug targets any subunit of a hexamer,
which is Z=6 and K=1. Thus the probability of remaining undrugged
6
targets will be q , where q represents the fraction of untargeted
hexamer subunits; in other words, the drug inhibition efficiency will
6
be 1-q , which increases following a power function compared to the
linear for conventional mono-subunit approaches.
Assuming that at least K copies of drugged subunits were needed to
deactivate the nanomachine or biocomplex, the probability of
functional biocomplexes in the presence of various ratios of inhibited
and wild-type subunits could be predicted from equation 2. When
K=1, it implies that drug binding to one subunit will inactivate the
subunit, and one drugged subunit per multi-subunit complex is
sufficient to inhibit the overall function of the complex. The inhibition
efficiency by drugs targeting multi-subunit biocomplexes with
stoichiometry of Z will equalͳ െ  ݍ௭ , as shown in table 1. An example
for such a probability calculation when Z = 6 and K = 1 is as follows:
since it was assumed that 6 (Z = 6) copies of subunits per element
were required for function and one drugged subunit (K = 1) was
sufficient to block its activity, all elements possessing 1 to 5 copies of
drugged subunits would be non-functional (Fig. 1C). Only those
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Table1. Predicted inhibition efficiency of drugs targeting biocomplex, K=1
Inhibited
subunit
(p)

Porbability of the multisubunit complex is active w ith:
Z=1, Z=2, Z=3, Z=4,
K=1 K=1 K=1 K=1

Z=5, Z=6, Z=7, Z=8, Z=9, Z=10, Z=11, Z=12,
K=1 K=1 K=1 K=1 K=1 K=1 K=1 K=1

0

1.00

1.00

1.00

1.00

1.00

1.00

1.00

1.00

1.00

1.00

1.00

1.00

0.1

0.90

0.81

0.73

0.66

0.59

0.53

0.48

0.43

0.39

0.35

0.31

0.28

0.2

0.80

0.64

0.51

0.41

0.33

0.26

0.21

0.17

0.13

0.11

0.09

0.07

0.3

0.70

0.49

0.34

0.24

0.17

0.12

0.08

0.06

0.04

0.03

0.02

0.01

0.4

0.60

0.36

0.22

0.13

0.08

0.05

0.03

0.02

0.01

0.01

0.00

0.00

0.5

0.50

0.25

0.13

0.06

0.03

0.02

0.01

0.00

0.00

0.00

0.00

0.00

0.6

0.40

0.16

0.06

0.03

0.01

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.7

0.30

0.09

0.03

0.01

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.8

0.20

0.04

0.01

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.9

0.10

0.01

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

1

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

complexes possessing 6 copies of normal subunits will be functional.
The chance for a complex containing 6 copies of unaffected subunits
6
in a population is q and the inhibition efficiency will be ͳ െ   ݍ.
Rationale behind selection of multi-subunit biocomplexes as
efficient drug targets
Mechanisms for drug inhibition of organism growth are to block or
stop an essential biological element from functioning. When a drug is
designed to target the subunit of a complex with targeting efficiency
p, a fraction of subunits will not interact with the drug (a percentile
given as q, p+q=1) and will remain active and exert their function
properly. Some biological elements are monomers containing only
one subunit, while other biological elements, such as the bio-motors
of hexameric AAA+ family, consist of multiple-subunits [19,34].
Conventional drugs are designed to inhibit pathogenesis through
targeting of a single subunit molecule, such as an enzyme or a
structural protein of a virus. In this situation, the inhibition efficiency
is proportional to the substrate targeting efficiency p and the effect is
proportional to the first order of p. As described above, in most
cases of sequential action or cooperatives in multiple subunit
complexes, inactivation of one, not all, of the subunits will result in
inhibition of its function. Thus, if complexes containing Z copies of
subunits exercise their function in a sequential and cooperative way,
then K=1, and the fraction of the uninhibited active biocomplex will
z
be q , a higher order with regards to the stoichiometry. The inhibition
proportion will equal ͳ െ  ݍ Ǥ
In this investigation, a well-defined in vitro phi29 viral assembly
system was used to represent a multi-subunit nano-machine target,
with the mutant component representing a target component that
have been inactivated by an effective drug. Then, the inhibition
efficiencies by targeting different elements of the phi29 DNA
packaging motor with different stoichiometry were compared. The
viral assembly competition assays combined with binomial
distribution analysis illustrated the concept that drug targeting
functional biological complexes of a higher-stoichiometry has a
higher efficiency than drug acting on a single subunit target.
When the target element is a monomer containing only one subunit,
the inhibition efficiency can be calculated through a binomial
distribution (equation 1), where p and q are the fractions of drugged
(substrate targeting efficiency) and undrugged (normal active
elements) subunits, respectively (p + q = 1).
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X = (p + q)

1
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population, considering that the total subunits in one element (Z) is 3

(1)

However, when the target element contains multiple subunits, a high
order binomial distribution (equation 2) is applied to calculate the
drug inhibition effect by finding the ratio of resulted active and
inactive complexes, where Z represents the total number of subunits
(the stoichiometry) in one biocomplex and M represents the number
of drugged subunits in one biocomplex.

X

( p  q) Z

Z

§Z·

¦ ¨¨ M ¸¸ p

M 0

©

Z M

¹

qM

Z

§

M 0

©

Z!

·

¦ ¨¨ M !(Z  M )! ¸¸ p

Z M

¹

qM

(2)

For example, if Z is 3, the probability of all combinations of drugged
subunits (M) and undrugged subunits (N; M + N = Z) in a given
biocomplex entity can be determined by the expansion of equation 2:
ሺ  ݍሻଷ ൌ ଷ  ͵ଶ  ݍ ͵ ݍଶ   ݍଷ ൌ ͳ . That is, the probability of a
complex element possessing three copies of drugged subunits in the
population isଷ , two copies of drugged and one copy of undrugged
or wild-type subunit is ͵ଶ  ݍ, one copy of drugged and two copies of
undrugged subunits is ͵ ݍଶ , and three copies of undrugged subunits
is  ݍଷ . Assuming there were 70% (p=0.7) of subunits inactivated by
bound drugs, and 30% (q=0.3) unaffected subunits in the population,
then the percentage of elements possessing at least two copies of
normal subunits would be the sum of those possessing one copy of
drugged and two copies of undrugged wild-type subunits,͵ ݍଶ , and
2
those possessing three copies of native subunits is  ݍଷ . That is 3pq
3
2
3
+ q = 3(0.7)(0.3) + (0.3) = 0.216 = 21.6% . In another example, if
one complex contains 6 subunits, and 5 out of the 6 subunits need to
remain uninhibited in order to be biologically functional, the active
complex ratio in the population will be the sum of: 1) the probability
of each element containing 5 undrugged subunits, and 2) the
probability of each element containing 6 undrugged subunits.
The probability X in the population displaying a certain combination
of undrugged versus drugged subunits can be predicted by a
binomial distribution, as shown in equation 2. Table 2 shows the
probability of a given element with M drugged and N undrugged

or 12.

The formula,

Ǩ
ǨǨ

  

(from equation 2) was used to

calculate each combination probability value, the coefficient

Z! in
M ! N!

this equation can also be calculated using Yang Hui Triangle, which
is also called Pascal's Triangle, or binomial distribution (Fig. 1B)[79].
In vitro virus assembly system used for testing the hypothesis
The highly sensitive in vitro phi29 assembly system was used to
determine the inhibition efficiency of drugs targeting multi-subunit
complexes [56,66,76,80]. Bacteriophage phi29 DNA packaging
motor contains one copy of genomic dsDNA, 6 copies of packaging
RNA, 6 copies of ATPase protein gp16 and more than 10000 copies
of ATP. The stoichiometry of RNA in phi29 has been proven by
extensive studies including single-molecule studies[81] AFM images
(Fig.1D) [82,83], pRNA crystal structure determination (Fig.1E) [84],
and mathematical studies [56]. The stoichiometry of gp16 in phi29
has been proven by multiple approaches including native gel binding,
capillary electrophoresis assays, Hill constant determination, and by
titration of mutant subunits using binomial distribution [19,33]. Many
other AAA+ superfamily members have been found to be hexamers
as well [85,86,87,88,89,90,91], such as a red type rubisco activase
AAA+ protein CbbX (Fig. 1F) [85], MecA-ClpC molecular machine
(Fig. 1G)[86]. The copy number of ATP molecules was calculated
based on the fact that 6 ATP molecules are required to package one
pitch of dsDNA with 10.5 basepairs (bp) [92], thus 1 ATP is used to
package 1.7 bp. The entire phi29 genome is composed of 19.4 kbp,
thus, it is expected that more than 10000 ATP molecules are
required to package the entire phi29 genome. The phi29 DNA nanomotor which packages an entire genomic DNA into the procapsid
can be treated as a disease model for drug inhibition efficiency
analysis.
In vitro testing of the hypothesis using DNA element with
stoichiometry of 1

subunits at increasing percentages of drugged subunits in the

Table 2. Probability of the complex containing M copies of drugged subunits and N copies of undrugged subunits
Z=3

Z=12

Inhibitied
Subunits
(p )

M =0,
N=3

M =1,
N=2

M =2,
N=1

M =3,
N=0

M =0,
N=12

M =1,
N=11

M =2,
N=10

M =3,
N=9

M =4,
N=8

M =5,
N=7

M =6,
N=6

M =7,
N=5

M =8,
N=4

M =9,
N=3

0

1.00

0.00

0.00

0.00

1.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

M =10, M =11, M =12,
N=2
N=1
N=0

0.1

0.73

0.24

0.03

0.00

0.28

0.38

0.23

0.09

0.02

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.2
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Figure 2: Theoretical plot (with variable Z) and empirical data to illustrate inhibition efficiency with drug targeting to genomic DNA ( Z-1). (A) Gel showing the
phi29 genome DNA treated with endonuclease EcoR1. (B) Plot of virion assembly derived from binomial distribution equation 2, which showed that the DNA
has stoichiometry of 1. (C) Viral assembly inhibition effect of mutant DNA as model of drugged component with Z=1, showing the linear relationship to p with
low slope.

The inhibition efficiency of drugs targeting a single subunit substrate
was tested by in vitro phi29 assembly inhibition by mutating the
genomic dsDNA (Fig. 2A). Various ratios of mutant DNA were mixed
with wild-type DNA in in vitro viral assembly assays. The empirical
curve of viral assembly efficiency against drugged mutant DNA ratio
fits well with the theoretical curve from binomial distribution for Z = 1
and K = 1 (Fig. 2B). This suggests that when designing drug
targeting the genomic DNA in phi29 nanomotor, it is expected to be a
first order inhibition response. Comparing the in vitro phi29 assembly
inhibition, by adding drugged mutant DNA, with simply diluting wildtype DNA concentration as a control, revealed that the drugged
mutant DNA didn’t cause much difference (Fig. 2C). The results
showed that the inhibition effect of drugs targeting the substrate with
stoichiometry of 1 is minimal.
In vitro testing of the hypothesis using RNA elements with
stoichiometry of 6
The pRNA of phi29 contains two domains; a head-loop domain

essential for procapsid binding and a helix domain essential for DNA
translocation (Fig. 3A, upper panel) [30,93,94]. The right-hand loop
and left-hand loop of two pairing pRNA molecules can interact with
each other by complementary base pairing. Extensive studies have
led to the conclusion that 6 copies of pRNA form a hexameric ring
which binds to the procapsid for virus activity [81,82,83,84]. Drugged
mutant pRNA was constructed by mutating 4 nucleotide sequences
at the 5’end region of pRNA (Fig. 3A, lower panel), which has been
shown to compete with wild-type pRNA for procapsid binding, but
was found to be deficient in allowing DNA packaging to occur [67].
The theoretical curves generated using the expansion of binomial
distribution equation while total subunit number Z is 6 and varying K
number from 1 to 6 are shown in Fig. 3B. Fitting the empirical data
from phage assembly efficiency at different ratios of drugged mutant
pRNAs into the theoretical curves, the empirical data fit into the
theoretical curve of Z = 6 and K = 1. It suggested that the pRNA
oligomer ring is composed of six copies of pRNA subunits and one
subunit of the pRNA multimer blockage is sufficient to block the
phage assembly activity. Comparing the empirical curve for viral

Figure 3: Theoretical plot (K=1 to 6) and empirical data to illustrate inhibition efficiency with drug targeting pRNA (Z=6). (A) The sequence and secondary
structure of wild-type pRNA of phi29 DNA packaging motor (upper panel) and inactive mutant pRNA with 4 bases mutation at 5’end of the DNA translocation
domain serving as a model of drugged inactive pRNA(lower panel). (B) Fitting the phage assembly inhibition result by inactive mutant pRNA with the theoretical
plots derived from Equation 2 matched with Z=6 and K=1. (C) Comparing the viral assembly inhibition effect by drugged pRNA at different concentration with
the undrugged pRNA with same dilution factor.
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assembly efficiency against different ratios of drugged mutant
pRNAs with the wild-type pRNA concentration dilution control,
addition of drugged mutant pRNA showed a much stronger inhibition
effect (Fig.3C).
To further prove the concept that drugs targeting biocomplex with
high stoichiometry causes stronger inhibition effect, antisense
oligonucleotides which can bind to pRNA molecules were designed
as mock drugs in the viral assembly assay. The oligonucleotides
P15, and P3 were designed to target the 5'-end and 3’-end regions
on pRNA, respectively. It was confirmed that the antisense
oligonucleotides can be hybridized to pRNA by gel shift assay (data
not shown). When mixing the antisense oligonucleotides with wildtype pRNA for in vitro phi29 assembly assay, complete inhibition
effects were shown by antisense oligonucleotides P15, and P3, but
not with the non-targeting control oligonucleotide P8[95]. By mixing
the non-targeting oligo P8 with pRNA, it generated plaques with
6
4.4×10 PFU on the plate.
In vivo testing of the hypothesis using RNA elements with
stoichiometry of 6
Formation of the hexameric ring of pRNA in the phi29 dsDNA
packaging motor has been discovered through biochemical and
structural studies [52,81,84,96,97,98,99,100,101,102,103] and
activity assays [94,104]. The observed high inhibition efficiency by
drugged mutant pRNA on phi29 assembly in vitro was striking
[67,105]. To test whether such a high level of inhibition was
attainable in vivo, pRBmutRNA plasmid expressing a pRNA with 4base mutation at the 3' end (Fig. 4A) was transformed into B. subtilis
DE1 cells. Plasmid pRBwtRNA contained the pRNA coding
sequence but do not express pRNA in B. subtilis DE1 cells, and
vector pRB381-L550 was introduced as well as a negative control.
The results showed that only cells harboring pRBmutRNA plasmid
were completely resistant to plaque formation by wild-type phi29
virus infection. Control cells, including B. subtilis 12A cells alone, B.
subtilis DE1 cells carrying vector pRB381-L550 alone, and cells
carrying a wild-type pRNA coding sequence but no expression
plasmid pRBwtRNA were all positive for plaque formation (Fig. 4B).
The ability of mutant pRNAs generated in cells by plasmid
pRBmutRNA completely inhibited plaque formation indicated that
hexameric pRNA in DNA packaging nano-motor may be a potential
target for developing potent antiviral agents [67].

Figure 4: Complete inhibition of viral assembly in vivo by mutant pRNA as a
model of drugged complex (Z=6). (A) Inactivation of pRNA by introducing a
4-nucleotide mutation at the 3’end. (B) Virion production by wild-type phi29
infection using host cell B. subtilis harboring plasmid expressing mutant
pRNA, wild-type pRNA, or plasmid only.
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In vitro testing of the hypothesis using the ATPase with
stoichiometry of 6
Hexameric folding of ATPase gp16 protein in the phi29 dsDNA
packaging motor has been discovered [1,19,33,35]. The hexameric
gp16 protein complex functions as ATPase like many other AAA+
superfamily members. ATP binding to one subunit of gp16 stimulates
the ATPase to change its conformation from having a lower affinity to
one having a higher affinity for dsDNA.
Determination of gp16 stoichiometry was carried out by in vitro
phage assembly assay and based on the binomial distribution of
wild-type and Walker B mutant gp16 [51]. Different ratios of drugged
Walker B mutant gp16 were mixed with undrugged gp16 to test the
inhibition efficiency of gp16 mutation on phi29 DNA packaging motor.
Assuming K equals 1 and the total copy number of gp16 (Z) is
between 1 and 12, twelve theoretical curves for the production of
phi29 virion against the ratio of the Walker B mutant corresponding
to the stoichiometry (Z) of 1 to 12 were generated according to
equation 2. The empirical data nearly perfectly overlapped the
theoretical curve of Z=6, K=1[51]. This data suggested that the
ATPase gp16 components of phi29 DNA packaging motor have a
stoichiometry of six, and only one copy of the drugged gp16 can
block the phi29 motor function. Comparing the inhibition effect of
adding mutant gp16 with wild-type gp16 at different concentrations, it
showed that adding mutant gp16 had a much stronger inhibition
effect than the wild-type gp16 concentration dilution control (Fig. 5A).
Comparing the inhibition effect of mutation on hexameric gp16 to the
effect of mutation on single subunit target DNA, the gp16 mutation
displayed a much stronger inhibition effect on virus assembly than
the same ratio of DNA mutation, indicating the hexameric ATPase
protein complex of virus assembly system should also be an efficient
target for generating new anti-virus drugs with high potency.
In vitro testing of the hypothesis using ATP with stoichiometry
of more than 10000
It has been reported that 6 ATP molecules are required to package
one pitch of dsDNA with 10.5bp [90], thus 1 ATP is used to package
1.7bp. As the entire phi29 genomic DNA has 19,000 base pairs, it is
expected that more than 10000 ATP molecules are required to
package the entire phi29 genome. Since concerning ATP, the
functional unit displayed in Fig 5 is the viral production expressed as
plaque-forming unit (PFU), so the production of one functional unit of
PFU require 10000 ATP subunits to package one genomic DNA.
Thus, the ATP in one phi29 nanomotor can be regarded as a
stoichiometry of 10000. One non-hydrolysable ATP analogue γ-SATP was treated as the drugged subunit that mixed with ATP at
different ratios to test the inhibition effect of γ-S-ATP on phi29
assembly efficiency. It was found that the inhibition curve of mutant
ATP fits into the theoretical curve between Z=100, K=1 and Z=60,
K=1 (Fig. 5B). The empirical ATP value derived from binomial
distribution assay was different from real condition, since the
binomial distribution equation was based on a condition that each
subunits has the same binding affinity to the biocomplex in the
targeted nanomotor, but due to the change of the γ-S-ATP structure,
it has a ATPase gp16 binding affinity lower than the normal ATP .
Furthermore, the affinity difference in each subunit has a
multiplicative effect in the nanomotor’s activity. Thus, there is a big
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Table 3. Comparison of proportion of non-inhibited complex betw een Z=6
and Z=1 w hen K=1 but having equal drug targeting efficacy
Substrate
targeting
efficacy (p)

P ro po rtio n o f
no n-inhibited
co mplex fro m
the po pulatio n
with Z=6

P ro po rtio n o f
no n-inhibited
co mplex fro m
the po pulatio n
with Z=1

Ratio o f the
pro po rtio ns o f no ninhibited co mplex
fro m the two
po pulatio ns with
Z=6 and Z=1

Reductio n (fo ld) in
pro po rtio n o f no ninhibited co mplex
co mparing Z=6
and Z=1

0

1

1

1

1

0.1

0.5314

0.9

0.5905

1.7

0.2

0.2621

0.8

0.3277

3.1

0.3

0.1176

0.7

0.1681

5.9

0.4

0.0467

0.6

0.0778

12.9

0.5

0.0156

0.5

0.0312

32

0.6

0.0041

0.4

0.0102

98

0.7

7.00E-04

0.3

0.0024

416

0.8

1.00E-04

0.2

0.0003

3333

0.9

1.00E-06

0.1

1.00E-05

10000
Z

Figure 5: Comparision of inhibition efficiency using targets with different Z
values. (A) Virion production inhibition effect of mutant gp16 (Z=6) at
different concentration. (B) Inhibition efficiency by γ-s-ATP with ATP with
high Z value. (C) Comparing the virus assembly inhibition effect by drugged
components of DNA, pRNA, gp16 and ATP with stoichiometry of 1, 6, 6,
10000 respectively.

discrepancy between the curves with predicted Z value and the
empirical Z value.
Comparing virus assembly inhibition effect using different
components, the γ-S-ATP showed a severe inhibition effect (Fig.
5C). Adding 20% of gamma-s-ATP nearly completely inhibited the
viral assembly. Comparing the inhibition effect targeting to ATP,
pRNA, ATPase gp16, and DNA with stoichiometry of 10000, 6, 6,
and 1, respectively, γ-S-ATP showed the strongest inhibition effect,
while drugged mutant pRNA and mutant gp16 showed stronger
inhibitory effect than mutant DNA (Fig.5C). For example, adding
20% mutant DNA caused 20% inhibition effect in viral assembly,
while 20% of drugged mutant pRNA exerted 74%of inhibition effect
on viral assembly and 20% of γ-S-ATP almost completely inhibited
the viral assembly, indicating the higher the stoichiometry, the
stronger the inhibition efficacy.

6

Z=6, K=1, the proportion of non-inhibited complex is q =0.4 =0.0041.
Therefore, 1-0.0041=99.59% of complex is inhibited. The ratio of the
proportions of non-inhibited complex equals 0.0041/0.4 = 0.0102,
indicating a 1/0.0102=98-fold decrease in the proportion of noninhibited complex. One more example is to use the drug targeting
efficiency p = 0.9 to compare the inhibition efficiency between two
groups with Z=6 and Z=1. For Z=6, K=1, the proportion of inhibited
Z
6
complex is 1-q =1-0.1 =0.999999. The proportion of non-inhibited
Z
6
complex is q =0.1 =1E-6. For Z=1, K=1, the proportion of inhibited
Z
complex is 1-q =1-0.1=0.9. The proportion of non-inhibited complex
Z
is q =0.1. The ratio of inhibition efficiency equals to 1E-6/0.1 = 1E-5,
indicating a 10000-fold increase in inhibition efficiency (Table 3).
The equation displays inhibitory effect with a power function of
stoichiometry since when K=1, the percentage of uninhibited
z
biocomplexes in the population equal to q . Since (P + q) = 1, thus q
z
≤ 1, thus the larger the Z, the smaller the value of q That is to say,
the higher the stoichiometry, the smaller number of the uninhibited
background will display. With the same substrate targeting efficacy,
p, the inhibition efficiency is determined by z, the power of the
equation component. The inhibitory effect is a power function
concerning the stoichiometry. Thu, the higher the stoichiometry, the
more efficient the inhibition comparing the drugs with same binding
affinity.
The half maximal inhibitory concentration (IC50) is commonly used to
evaluate drug effect, which quantitatively indicates how much of a
particular drug is needed to inhibit a given biological process by half.

Mathematical reasoning for the increase of inhibition efficacy

If we denote

as the percentage of drugged subunit needed to

Using a biological complex with higher stoichiometry as drug target
will substantially reduce the proportion of non-inhibited complex. For
Z
K=1, the proportion of non-inhibited complex is q . Table 3
compares the proportion of non-inhibited complex from two
populations with Z=6 and Z=1, respectively, with varied substrate
targeting efficiency (p) when K =1. For example, when q=0.4, the
Z
1
proportion of non-inhibited complex is q =0.4 =0.4 for Z=1, K=1.
Therefore, only 1-0.4=60% of complex is inhibited. In contrast, for

reach to 50% inhibition in the in vitro assay in the defined system,
thus

.Solving

this

equation,

. Figure 6 shows the relationship between
stoichiometry (Z) and drug targeting level p to reach the inhibition
effect (IC), where p is the combined result of drug binding efficacy
and

drug

concentration

(dosage).

When

biocomplexes

with

stoichiometry of Z are used as drug targets, the dosage of drug or
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the drug binding affinity presented by percentage of drugged
subunits to reach IC50, IC25, or IC75 decreases. This clearly shows
that as Z increases,

decreases (Fig. 6), and hence the drug

is more potent.
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which quantitatively indicates how much of a particular drug is
needed to inhibit a given biological process by half. It is universally
used as a measure of drug potency in pharmacological research.
Another important parameter is the median lethal dose (LD50), which
is also known as 50% of lethal concentration (LC50). LD50 is
frequently used to indicate a substance's acute toxicity. Obviously,
the usefulness of a drug will dependent on the ratio of LD50 to IC50.
The larger this ratio, the safer the drug. By ways of increasing the
inhibition efficiency through targeting to the components with high
stoichiometry, the IC50 of a drug will decrease. As a result, lower
concentration of drug will be required for reaching a desired effect,
resulting in a reduced toxicity of the drug.
Most of current anti-cancer, anti-virus or anti-bacteria drugs target
single enzymes or single proteins. Our data showed that drugs
selected to target components, biocomplexes, or nano-machines
with high copy numbers could lead to a much higher efficacy, and it
could potentially solve the problem of low drug effect and multi-drug
resistance.
Conclusions

Figure 6: Relationship between stoichiometry (Z) and drug targeting level (p,
a combined result of drug binding efficacy and drug concentration) to reach
the inhibition effect (IC).

Discussion
Aiming to find a method for developing drugs with ultra-high potency,
we proposed that the inhibition efficiency of a given drug depends on
stoichiometry of the biocomplex or bio-machine that was used as
drug target. Here the definition of the stoichiometry is different from
conventional definition of stoichiometry used to evaluate drug
efficiency. Conventional thinking in drug development emphasizes
stoichiometry which refers to the number of drug binding per target
molecule, which is also known as Bmax. In this study the definition of
stoichiometry refers to the copy number of subunit within a
biocomplex that serves as drug target. We used phi29 viral
components with a series of variable but known stoichiometry as
mock drug targets to test the hypothesis. Both in vitro and in vivo
virion assembly assays were employed to compare the inhibition
efficiency targeting to components with different numbers of subunit
stoichiometry. Viral inhibition efficiency was analyzed with Yang Hui's
(Pascal’s) Triangle (or knowns as binomial distribution). It was found
that inhibition efficiency on virus replication correlates to the
component stoichiometry of nano-machine as drug target. It
displayed power law inhibitory effect since when K=1, the
percentage of uninhibited biocomplexes in the population equal to
z
q . With the same q and same K value, the inhibition efficiency is
determined by z, the number of subunits within the biocomplex or the
bio-machine as drug target. Here z serves as the power in the
equation, thus, the inhibitory effect is the power of the stoichiometry.
Empirical data demonstrated that the target with thousand-subunits
shows higher inhibition effect than the targets with six subunits, and
in turn higher than the target with single subunit.
In evaluation of drug effect, two parameters were commonly used.
One is the half maximal inhibitory concentration (IC50),

Targeting the functional biological units with higher stoichiometries
will have a higher efficiency of inhibition. The inhibition effect is
power, other than proportional, and the power, is the copy number of
the drug-targeted element of the machine. The new theory
developed herein suggests that potent drugs can be developed by
targeting biocomplex with high stoichiometry, and a complete
inhibition of virus, bacterium, or cancer is possible if a bio-machine
with high stoichiometry is identified. Since bio-motors share certain
common structure and operation mechanism in viruses, bacteria,
and cells, this approach should have general application in drug
development.
Future Perspective
Living systems contain many elegant arrays, motors and
nanomachines that are multi-subunit complex. As reported here,
these biocomplex with high copy number of components can serve
as potent drug targets. For example, most members of the AAA+
family are hexamer [19,87,88,106,107,108]. However, these
machines are common in living systems therefore the specificity and
toxicity is an issue. For bacteria and virus, since our goal is to kill
them nonexclusively, the specificity and toxicity is not an issue as
long as the target biocomplex is not identical to that in human body.
For cancers drugs, as long as a mutation is found in the multiplesubunit biocomplex, it will be an ideal target for potent drug.

Executive summary
Aim
• A method for developing potent drugs is sought.
Hypothesis
• Drug inhibition potency depends on the stoichiometry of the
targeted biocomplex.
Approach:
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• Phi29 viral components with variable stoichiometry were used
as model to prove the hypothesis
• Virion assembly efficiency was assayed and analyzed with
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3. Guo PX , Lee TJ. Viral nanomotors for packaging of dsDNA and dsRNA.
Mol.Microbiol. 64, 886-903 (2007).
4. Molineux IJ , Panja D. Popping the cork: mechanisms of phage genome
ejection. Nat Rev.Microbiol. 11(3), 194-204 (2013).
5. Lee BS, Lee SC, Holliday LS. Biochemistry of mechanoenzymes: Biological
motors for nanotechnology. Biomedical Microdevices 5(4), 269-280 (2003).
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(2010).

Results:
• Inhibition efficiency displayed a power function of the
stoichiometry of the target biocomplexes. The uninhibited
z
biocomplex in population can equals to q . Thus, the inhibitory
effect is a power of the stoichiometry.
• Targets with thousand-subunit showed higher inhibition effect than
with six subunits, and in turn higher than target with single subunit.
• A complete inhibition of virus, bacterium, or cancer was
demonstrated when targets with high stoichiometry was used as
target.
Conclusion
• Drug inhibition potency depends on the stoichiometry of the
targeted components of the biocomplex or nano-machine.
• The inhibition effiect displayed a power funciton of the
stoichiometry of the target biocomplex.
• Since bio-motors share certain common structure and operation
mechanism in viruses, bacteria, and cells, this approach should
have general application in drug development.

Acknowledgements
The authors would like to thank Timothy S. Tracy for a critical review
on the manuscript and a very insightful and impressive comments of
the approach reported; Esther Penni Black, Patrick McNamara,
Mario Vieweger, Joseph Chappell, Brad Anderson, Chaoyuan Liu,
for constructive comments on the manuscript and helpful discussion;
Ashwani Sharma, Daniel Binzel, Daniel Jasinski and Jordan Surface
for editing and formatting this manuscript, and Zhengyi Zhao for the
drawing of figures. This publication was made possible by grants
from NIH/NIBIB EB012135, EB003730, and NIH/NCI CA151648 to
Peixuan Guo, and the Markey Cancer Grant P30CA177558 to B.
Mark Evers.
Funding to Peixuan Guo's Endowed Chair in
Nanobiotechnology position is by the William Fairish Endowment
Fund. Peixuan Guo is a co-founder of Kyline Therapeutic, Inc,
Biomotor and RNA Nanotechnology Development Corp. Ltd, and
RNA Nano, LLC..

References
1. Guo P, Zhao Z, Haak J et al. Common Mechanisms of DNA translocation
motors in Bacteria and Viruses Using One-way Revolution Mechanism without
Rotation. Biotechnology Advances 32, 853-872 (2014).
** This review reports that revolution mechanism is commonly used in bacteria
and viruses which avoid DNA coiling in translocation the lengthy genomic
dsDNA helix.
2. Jankowsky E, Fairman ME, Yang Q. RNA Helicases: Versatile ATP-Driven
Nanomotors. J.Nanosci.Nanotechnol. 5, 1983-1989 (2005).

7. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic
exchange between cells. Nat Cell Biol 9(6), 654-659 (2007).
8. Wendler F, Bota-Rabassedas N, Franch-Marro X. Cancer becomes
wasteful: emerging roles of exosomes(dagger) in cell-fate determination.
J.Extracell.Vesicles. 2 (22390), 1-9 (2013).
9. Fang H, Jing P, Haque F, Guo P. Role of channel Lysines and "Push
Through a One-way Valve" Mechanism of Viral DNA packaging Motor.
Biophysical Journal 102, 127-135 (2012).
10. Zhang H, Schwartz C, De Donatis GM, Guo P. "Push Through One-Way
Valve" Mechanism of Viral DNA Packaging. Adv.Virus Res 83, 415-465 (2012).
11. Jing P, Haque F, Shu D, Montemagno C, Guo P. One-Way Traffic of a
Viral Motor Channel for Double-Stranded DNA Translocation. Nano Lett. 10,
3620-3627 (2010).
12. Kasianowicz JJ, Brandin E, Branton D, Deamer DW. Characterization of
individual polynucleotide molecules using a membrane channel.
Proc.Natl.Acad.Sci.U.S.A 93(24), 13770-13773 (1996).
13. Butler TZ, Pavlenok M, Derrington IM, Niederweis M, Gundlach JH. Singlemolecule DNA detection with an engineered MspA protein nanopore.
Proc.Natl.Acad.Sci.U.S.A 105(52), 20647-20652 (2008).
14. Wendell D, Jing P, Geng J et al. Translocation of double-stranded DNA
through membrane-adapted phi29 motor protein nanopores. Nat.Nanotechnol.
4, 765-772 (2009).
15. Pastoriza-Gallego M, Rabah L, Gibrat G et al. Dynamics of unfolded
protein transport through an aerolysin pore. J.Am.Chem.Soc. 133(9), 29232931 (2011).
16. Ezzell C. How Chaperonins Monitor Their Protein Charges. The Journal of
NIH Research 6, 31-34 (1994).
17. Maga G , Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer
with many partners. J.Cell Sci. 116(Pt 15), 3051-3060 (2003).
18. Rubinchik S, Parris W, Gold M. The in vitro ATPases of bacteriophage l
terminase and its large subunit, gene product A. J Biol Chem 269, 1358613593 (1994).
19. Schwartz C, De Donatis GM, Fang H, Guo P. The ATPase of the phi29
DNA-packaging motor is a member of the hexameric AAA+ superfamily.
Virology 443, 20-27 (2013).
* This paper confirmed the stoichiometry of ATPase in phi29 motor is a
hexamer and provided data suggesting that the phi29 motor ATPase belongs
to classical hexameric AAA+ superfamily.
20. Sun L, Young LN, Zhang X et al. Icosahedral bacteriophage PhiX174 forms
a tail for DNA transport during infection. Nature 505(7483), 432-435 (2014).
21. Haque F, Li J, Wu H-C, Liang X-J, Guo P. Solid-state and biological
nanopore for real-time sensing of single chemical and sequencing of DNA.
Nano Today 8, 56-74 (2013).
22. Haque F, Lunn J, Fang H, Smithrud D, Guo P. Real-Time Sensing and
Discrimination of Single Chemicals Using the Channel of Phi29 DNA
Packaging Nanomotor. ACS Nano 6, 3251-3261 (2012).
23. Wang S, Haque F, Rychahou PG, Evers BM, Guo P. Engineered
Nanopore of Phi29 DNA-Packaging Motor for Real-Time Detection of Single
Colon Cancer Specific Antibody in Serum. ACS Nano 7, 9814-9822 (2013).
24. Fennimore AM, Yuzvinsky TD, Han WQ, Fuhrer MS, Cumings J, Zettl A.
Rotational actuators based on carbon nanotubes. Nature 424, 408-410 (2003).
25. Craighead HG. Nanoelectromechaical systems. Science 290, 1532-1536
(2000).

10
Nanomedicine(Lond.) (2015) 10(12), 1881-1897

ISSN 1743-5889

New Approach to Develop Ultra-high Inhibitory Drug

Shu et al, Nanomedicine

26. Gerion D, Parak WJ, Williams SC, Zanchet D, Micheel CM, Alivisatos AP.
Sorting fluorescent nanocrystals with DNA. J Am.Chem Soc. 124, 7070-7074
(2002).

46. Guo P, Haque F, Hallahan B, Reif R, Li H. Uniqueness, advantages,
challenges, solutions, and perspectives in therapeutics applying RNA
nanotechnology. Nucleic Acid Ther. 22(4), 226-245 (2012).

27. Geng J, Wang S, Fang H, Guo P. Channel size conversion of Phi29 DNApackaging nanomotor for discrimination of single- and double-stranded nucleic
acids. ACS Nano 7(4), 3315-3323 (2013).

47. Lusky K. HIV's potent cocktail. Contemp.Longterm.Care 22(12), 59(1999).

28. McNally B, Singer A, Yu Z, Sun Y, Weng Z, Meller A. Optical recognition of
converted DNA nucleotides for single-molecule DNA sequencing using
nanopore arrays. Nano Lett. 10(6), 2237-2244 (2010).
29. Chandler EL, Smith AL, Burden LM, Kasianowicz JJ, Burden DL.
Membrane surface dynamics of DNA-threaded nanopores revealed by
simultaneous single-molecule optical and ensemble electrical recording.
Langmuir 20(3), 898-905 (2004).
30. Shu D, Shu Y, Haque F, Abdelmawla S, Guo P. Thermodynamically stable
RNA three-way junctions for constructing multifuntional nanoparticles for
delivery of therapeutics. Nature Nanotechnology 6, 658-667 (2011).
31. Haque F, Shu D, Shu Y et al. Ultrastable synergistic tetravalent RNA
nanoparticles for targeting to cancers. Nano Today 7, 245-257 (2012).
32. Crozat E , Grainge I. FtsK DNA translocase: the fast motor that knows
where it's going. Chembiochem. 11, 2232-2243 (2010).
33. Schwartz C, De Donatis GM, Zhang H, Fang H, Guo P. Revolution rather
than rotaton of AAA+ hexameric phi29 nanomotor for viral dsDNA packaging
without coiling. Virology 443, 28-39 (2013).
* This paper shows how the nanomotor in phi29 virus works with a revolution
mechanism using six copies of ATPase.
34. Hanson PI , Whiteheart SW. AAA+ proeins: have engine, will work.
Nat.Rev.Mol Cell Biol. 6, 519-529 (2005).
35. Guo P, Schwartz C, Haak J, Zhao Z. Discovery of a new motion
mechanism of biomotors similar to the earth revolving around the sun without
rotation. Virology 446, 133-143 (2013).
36. De-Donatis G, Zhao Z, Wang S et al. Finding of widespread viral and
bacterial revolution dsDNA translocation motors distinct from rotation motors
by channel chirality and size. Cell Biosci 4, 30- (2014).
** This paper reports that the revolution motor nanomachine is widespread
among biological systems, and can be distinguished from rotation motors by
channel size and chirality.
37. Batra S, Adekola KUA, Rosen ST, Shanmugam M. Cancer Metabolism as
a Therapeutic Target. ONCOLOGY-NEW YORK 27, 460-467 (2013).
38. Buskin SE, Zhang S, Thibault CS. Prevalence of and viral outcomes
associated with primary HIV-1 drug resistance. Open.AIDS J. 6, 181-187
(2012).
39. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE, Jr. Trends in
antimicrobial drug development: implications for the future. Clin.Infect.Dis.
38(9), 1279-1286 (2004).
40. Lakshmanan M , Xavier AS. Bedaquiline - The first ATP synthase inhibitor
against multi drug resistant tuberculosis. J.Young.Pharm. 5(4), 112-115
(2013).
41. Aird KM, Ding XY, Baras A et al. Trastuzumab signaling in ErbB2overexpressing inflammatory breast cancer correlates with X-linked inhibitor of
apoptosis protein expression. Molecular Cancer Therapeutics 7(1), 38-47
(2008).
42. Park SH, Kim H, Song BJ. Down regulation of bcl2 expression in invasive
ductal carcinomas is both estrogen- and progesterone-receptor dependent and
associated with poor prognostic factors. Pathol.Oncol.Res. 8(1), 26-30 (2002).

48. Chatterjee A, Chattopadhyay D, Chakrabarti G. miR-17-5p Downregulation
Contributes to Paclitaxel Resistance of Lung Cancer Cells through Altering
Beclin1 Expression. PLoS ONE 9(4), e95716- (2014).
49. Sanchez C, Chan R, Bajgain P et al. Combining T-cell immunotherapy and
anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic.Dis.
16(2), 123-31 (2013).
50. Ito M, Zhao N, Zeng Z, Chang CC, Zu Y. Synergistic growth inhibition of
anaplastic large cell lymphoma cells by combining cellular ALK gene silencing
and a low dose of the kinase inhibitor U0126. Cancer Gene Ther. 17(9),633-44
(2010).
51. Fang H, Zhang P, Huang LP et al. Binomial distribution for quantification of
protein subunits in biological nanoassemblies and functional nanomachines.
Nanomedicine. 10(7),1433-40 (2014).
**This is the first report to describe how to use the Yang Hui's Triangle
(binomial distribution) to determine the stoichiometry of protein subunits in
biocomplex. It precisely confirmed that phi29 motor contains six copies of
ATPase gp16 and one mutant subunit would cause motor to stop.
52. Guo P, Zhang C, Chen C, Trottier M, Garver K. Inter-RNA interaction of
phage phi29 pRNA to form a hexameric complex for viral DNA transportation.
Mol.Cell. 2, 149-155 (1998).
* This is the first paper to reveal that the pRNA of phi29 DNA packaging
motorfirms a hexameric ring, and prove-of -concept of RNA nanotechnology
since this paper shows that by bottom-up assembly, the RNA nanoparticles of
dimers, trimers and hexamers can be constructed using the reenginered RNA
fragments derived from phi29 motor pRNA.
53. Hugel T, Michaelis J, Hetherington CL et al. Experimental test of connector
rotation during DNA packaging into bacteriophage phi29 capsids. Plos Biology
5, 558-567 (2007).
54. Xiao F, Moll D, Guo S, Guo P. Binding of pRNA to the N-terminal 14 amino
acids of connector protein of bacterial phage phi29. Nucleic Acids Res 33,
2640-2649 (2005).
55. Guo P, Peterson C, Anderson D. Prohead and DNA-gp3-dependent
ATPase activity of the DNA packaging protein gp16 of bacteriophage phi29. J
Mol Biol 197, 229-236 (1987).
56. Trottier M , Guo P. Approaches to determine stoichiometry of viral
assembly components. J.Virol. 71, 487-494 (1997).
*This is the first report to describe how to use the Yang Hui's Triangle
(binomial distribution) to determine the stoichiometry of biocomplex or
nanomachine.
57. Guo P, Peterson C, Anderson D. Initiation events in in vitro packaging of
bacteriophage phi29 DNA-gp3. J Mol Biol 197, 219-228 (1987).
58. Zhao Z, Khisamutdinov E, Schwartz C, Guo P. Mechanism of one-way
traffic of hexameric phi29 DNA packaging motor with four electropositive
relaying layers facilitating anti-parallel revolution. ACS Nano 7, 4082-4092
(2013).
59. Guo P, Grainge I, Zhao Z, Vieweger M. Two classes of nucleic acid
translocation motors: rotation and revolution without rotation. Cell Biosci. 4(1),
54- (2014).
60. Casjens SR. The DNA-packaging nanomotor of tailed bacteriophages. Nat
Rev.Microbiol. 9(9), 647-657 (2011).

43. Akinc A, Querbes W, De S et al. Targeted delivery of RNAi therapeutics
with endogenous and exogenous ligand-based mechanisms. Mol.Ther. 18(7),
1357-1364 (2010).

61. Boal AK, Ilhan F, DeRouchey JE, Thurn-Albrecht T, Russell TP, Rotello
VM. Self-assembly of nanoparticles into structured spherical and network
aggregates. Nature 404(6779), 746-748 (2000).

44. Aronov O, Horowitz AT, Gabizon A, Gibson D. Folate-targeted PEG as a
potential carrier for carboplatin analogs. Synthesis and in vitro studies.
Bioconjugate Chem. 14(3), 563-574 (2003).

62. Holohan C, Van SS, Longley DB, Johnston PG. Cancer drug resistance: an
evolving paradigm. Nat.Rev.Cancer 13(10), 714-726 (2013).

45. Bae YH , Park K. Targeted drug delivery to tumors: myths, reality and
possibility. J.Control Release 153(3), 198-205 (2011).

63. Guo P, Grimes S, Anderson D. A defined system for in vitro packaging of
DNA-gp3 of the Bacillus subtilis bacteriophage phi29. Proc.Natl.Acad.Sci.USA
83, 3505-3509 (1986).

11
Nanomedicine(Lond.) (2015) 10(12), 1881-1897

ISSN 1743-5889

New Approach to Develop Ultra-high Inhibitory Drug

Shu et al, Nanomedicine

64. Zhang CL, Lee C-S, Guo P. The proximate 5' and 3' ends of the 120-base
viral RNA (pRNA) are crucial for the packaging of bacteriophage f29 DNA.
Virology 201, 77-85 (1994).

85. Mueller-Cajar O, Stotz M, Wendler P, Hartl FU, Bracher A, Hayer-Hartl M.
Structure and function of the AAA+ protein CbbX, a red-type Rubisco activase.
Nature 479, 194-199 (2011).

65. Shu D, Huang L, Hoeprich S, Guo P. Construction of phi29 DNA-packaging
RNA (pRNA) monomers, dimers and trimers with variable sizes and shapes as
potential parts for nano-devices. J.Nanosci.Nanotechnol. 3, 295-302 (2003).

86. Wang F, Mei Z, Qi Y et al. Structure and mechanism of the hexameric
MecA-ClpC molecular machine. Nature 471, 331-335 (2011).

66. Lee CS , Guo P. A highly sensitive system for the assay of in vitro viral
assembly of bacteriophage phi29 of Bacillus subtilis. Virology 202, 1039-1042
(1994).
67. Trottier M, Zhang CL, Guo P. Complete inhibition of virion assembly in vivo
with mutant pRNA essential for phage phi29 DNA packaging. J.Virol. 70, 55-61
(1996).
68. Chen C , Guo P. Sequential action of six virus-encoded DNA-packaging
RNAs during phage phi29 genomic DNA translocation. J.Virol. 71(5), 38643871 (1997).
69. Stitt BL , Xu Y. Sequential hydrolysis of ATP molecules bound in
interacting catalytic sites of Escherichia coli transcription termination protein
Rho. J.Biol.Chem. 273(41), 26477-26486 (1998).
70. Kammerer RA, Schulthess T, Landwehr R, Lustig A, Fischer D, Engel J.
Tenascin-C hexabrachion assembly is a sequential two-step process initiated
by coiled-coil alpha-helices. J.Biol.Chem. 273(17), 10602-10608 (1998).
71. Lisal J , Tuma R. Cooperative mechanism of RNA packaging motor. J Biol
Chem 280, 23157-23164 (2005).
72. Zhang Z, Lewis D, Strock C et al. Detailed characterization of the
cooperative mechanism of Ca(2+) binding and catalytic activation in the Ca(2+)
transport (SERCA) ATPase. Biochemistry 39(30), 8758-8767 (2000).
73. Sun H , Squier TC. Ordered and cooperative binding of opposing globular
domains of calmodulin to the plasma membrane Ca-ATPase. J.Biol.Chem.
275(3), 1731-1738 (2000).
74. Hiller R , Carmeli C. Kinetic analysis of cooperative interactions induced by
Mn2+ binding to the chloroplast H(+)-ATPase. Biochemistry 29(26), 6186-6192
(1990).
75. Persechini A , Hartshorne DJ. Cooperative behavior of smooth muscle
myosin. Fed.Proc. 41(12), 2868-2872 (1982).
76. Lee CS , Guo P. Sequential interactions of structural proteins in phage
phi29 procapsid assembly. J.Virol. 69, 5024-5032 (1995).
77. Casjens S, Hendrix R. Control mechanisms in dsDNA bacteriophage
assembly. In: The Bacteriophages Vol.1. Calendar R (Eds.). Plenum Pubishing
Corp., 15-92 (1988)

87. Aker J, Hesselink R, Engel R et al. In vivo hexamerization and
characterization of the Arabidopsis AAA ATPase CDC48A complex using
forster resonance energy transfer-fluorescence lifetime imaging microscopy
and fluorescence correlation spectroscopy. Plant Physiology 145(2), 339-350
(2007).
88. Willows RD, Hansson A, Birch D, Al-Karadaghi S, Hansson M. EM single
particle analysis of the ATP-dependent BchI complex of magnesium chelatase:
an AAA(+) hexamer. J Struct Biol 146(1-2), 227-233 (2004).
89. Chen YJ, Yu X, Egelman EH. The hexameric ring structure of the
Escherichia coli RuvB branch migration protein. J.Mol.Biol. 319(3), 587-591
(2002).
90. Happonen LJ, Oksanen E, Liljeroos L, Goldman A, Kajander T, Butcher SJ.
The structure of the NTPase that powers DNA packaging into Sulfolobus
turreted icosahedral virus 2. J.Virol. 87, 8388-8398 (2013).
91. Snider J, Thibault G, Houry WA. The AAA+ superfamily of functionally
diverse proteins. Genome Biol 9(4), 216-216 (2008).
92. Schwartz C, Fang H, Huang L, Guo P. Sequential action of ATPase, ATP,
ADP, Pi and dsDNA in procapsid-free system to enlighten mechanism in viral
dsDNA packaging. Nucleic Acids Res. 40, 2577-2586 (2012).
93. Trottier M, Garver K, Zhang C, Guo P. DNA-packaging pRNA as target for
complete inhibition of viral assembly in vitro and in vivo. Nucleic Acids
Symposium Series 36, 187-189 (1997).
94. Chen C, Zhang C, Guo P. Sequence requirement for hand-in-hand
interaction in formation of pRNA dimers and hexamers to gear phi29 DNA
translocation motor. RNA 5, 805-818 (1999).
95. Zhang CL, Trottier M, Guo PX. Circularly permuted viral pRNA active and
specific in the packaging of bacteriophage Phi29 DNA. Virology 207, 442-451
(1995).
96. Zhang F, Lemieux S, Wu X et al. Function of hexameric RNA in packaging
of bacteriophage phi29 DNA in vitro. Mol.Cell. 2, 141-147 (1998).
97. Hendrix RW. Bacteriophage DNA packaging: RNA gears in a DNA
transport machine (Minireview). Cell 94, 147-150 (1998).
98. Bourassa N , Major F. Implication of the prohead RNA in phage phi29 DNA
packaging. Biochimie 84, 945-951 (2002).

78. Qian X, Ren Y, Shi Z et al. Sequence-dependent synergistic inhibition of
human glioma cell lines by combined temozolomide and miR-21 inhibitor gene
therapy. Mol Pharm. 9(9), 2636-2645 (2012).

99. Xiao F, Zhang H, Guo P. Novel mechanism of hexamer ring assembly in
protein/RNA interactions revealed by single molecule imaging. Nucleic Acids
Res 36, 6620-6632 (2008).

79. Zhang H, Shu D, Huang F, Guo P. Instrumentation and metrology for
single RNA counting in biological complexes or nanoparticles by a single
molecule dual-view system. RNA 13, 1793-1802 (2007).

100. Moll D , Guo P. Grouping of Ferritin and Gold Nanoparticles Conjugated
to pRNA of the Phage phi29 DNA-packaging motor. J Nanosci and Nanotech
(JNN) 7, 3257-3267 (2007).

80. Chen C, Trottier M, Guo P. New approaches to stoichiometry determination
and mechanism investigation on RNA involved in intermediate reactions.
Nucleic Acids Symposium Series 36, 190-193 (1997).

101. Ibarra B, Caston J.R., Llorca O., Valle M, Valpuesta J.M., Carrascosa J.L.
Topology of the components of the DNA packaging machinery in the phage
phi29 prohead. J.Mol.Biol. 298, 807-815 (2000).

81. Shu D, Zhang H, Jin J, Guo P. Counting of six pRNAs of phi29 DNApackaging motor with customized single molecule dual-view system. EMBO J.
26, 527-537 (2007).

102. Xiao F, Demeler B, Guo P. Assembly Mechanism of the Sixty-Subunit
Nanoparticles via Interaction of RNA with the Reengineered Protein Connector
of phi29 DNA-Packaging Motor. ACS Nano. 4(6), 3293-3301 (2010).

* This is the first report describing the use of single fluorophore photobleaching
technique to count subunits in biocomplex, and documents the "seeing is
believing" to confirm that phi29 DNA packaging motor contains six copies of
packaging pRNA.

103. Fang Y, Cai Q, Qin PZ. The procapsid binding domain of phi29 packaging
RNA has a modular architecture and requires 2'-hydroxyl groups in packaging
RNA interaction. Biochemistry 44, 9348-9358 (2005).

82. Shu Y, Haque F, Shu D et al. Fabrication of 14 Different RNA
Nanoparticles for Specific Tumor Targeting without Accumulation in Normal
Organs. RNA 19, 766-777 (2013).
83. Shu Y, Shu D, Haque F, Guo P. Fabrication of pRNA nanoparticles to
deliver therapeutic RNAs and bioactive compounds into tumor cells. Nat
Protoc. 8(9), 1635-1659 (2013).
84. Zhang H, Endrizzi JA, Shu Y et al. Crystal Structure of 3WJ Core
Revealing Divalent Ion-promoted Thermostability and Assembly of the Phi29
Hexameric Motor pRNA. RNA 19, 1226-1237 (2013).

104. Chen C, Sheng S, Shao Z, Guo P. A dimer as a building block in
assembling RNA: A hexamer that gears bacterial virus phi29 DNAtranslocating machinery. J Biol Chem 275(23), 17510-17516 (2000).
105. Zhang CL, Garver K, Guo P. Inhibition of phage phi29 assembly by
antisense oligonucleotides targeting viral pRNA essential for DNA packaging.
Virology 211, 568-576 (1995).
106. White SR , Lauring B. AAA+ ATPases: Achieving diversity of function with
conserved machinery. Traffic 8(12), 1657-1667 (2007).
107. Iyer LM, Leipe DD, Koonin EV, Aravind L. Evolutionary history and higher
order classification of AAA plus ATPases. J Struct Biol 146(1-2), 11-31 (2004).

12
Nanomedicine(Lond.) (2015) 10(12), 1881-1897

ISSN 1743-5889

New Approach to Develop Ultra-high Inhibitory Drug

Shu et al, Nanomedicine

108. Liu Y, Huang T, MacMorris M, Blumenthal T. Interplay between AAUAAA
and the trans-splice site in processing of a Caenorhabditis elegans operon premRNA. RNA. 7(2), 176-181 (2001).

13
Nanomedicine(Lond.) (2015) 10(12), 1881-1897

ISSN 1743-5889

